Daiichi Sankyo Co Ltd 2017 IR
The report highlights Daiichi Sankyo's progress during fiscal 2016, the first year of its 5-Year Business Plan, as it transitions toward its 2025 Vision of becoming a Global Pharma Innovator with competitive advantage in oncology. Key achievements include the rapid growth of its anticoagulant edoxaban (LIXIANA) and promising clinical results for its antibody-drug conjugate (ADC) flagship asset, DS-8201. The company also ranked first in pharmaceutical revenue and medical representative evaluation in Japan. Additionally, Daiichi Sankyo advanced its environmental goals, reducing CO2 emissions by 4.0% compared to fiscal 2015.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2017
Type: IR
Pages: 59
Back to company
Daiichi Sankyo Co Ltd
Value Report
The report highlights Daiichi Sankyo's progress during fiscal 2016, the first year of its 5-Year Business Plan, as it transitions toward its 2025 Vision of becoming a Global Pharma Innovator with competitive advantage in oncology. Key achievements include the rapid growth of its anticoagulant edoxaban (LIXIANA) and promising clinical results for its antibody-drug conjugate (ADC) flagship asset, DS-8201. The company also ranked first in pharmaceutical revenue and medical representative evaluation in Japan. Additionally, Daiichi Sankyo advanced its environmental goals, reducing CO2 emissions by 4.0% compared to fiscal 2015.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees